CareDx announced the finalization of Medicare Local Coverage Determination (LCD) for its molecular testing services for solid organ allograft rejection. This policy affirms coverage for CareDx's transplant surveillance offerings in kidney, heart, and lung, ensuring continued reimbursement for these critical diagnostic tests.
CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process for its molecular testing services used to detect solid organ allograft rejection. This is a significant positive development because it confirms continued Medicare reimbursement for CareDx's core transplant surveillance products across kidney, heart, and lung. This eliminates a potential overhang of uncertainty regarding future coverage and ensures a stable revenue stream from a major payer. For traders, this reduces regulatory risk and provides clarity on the company's financial outlook, likely leading to a positive short-term reaction and strengthening long-term investor confidence in CDNA's market position.